Net loss widens 31% to $96.4M as G&A spending doubles for H2 2026 commercial launch

Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~2 min read

Key Changes

• high

  Three bezuclastinib NDAs under FDA review with PDUFA dates in Q4 2026 (NonAdvSM Dec 30, GIST Nov 30 with Priority Review); company building internal commercial organization for H2 2026 U.S. launch pending approval.

  MD&A: NDA filings and commercial launch timeline verify on EDGAR →
• high

  Net loss for Q2 2026 was $96.4M, up 137.3% YoY, driven by G&A expense doubling to $31.8M (from $13.4M) as the company invests in commercial readiness (personnel, infrastructure) for the anticipated bezuclastinib launch.

  MD&A: Operating loss and G&A expense verify on EDGAR →
• high

  Cash runway extended to late 2028 (from prior guidance of 'into 2027') with $792.3M.

  MD&A: Cash runway verify on EDGAR →